SPX3,831.39+6.06 0.16%
DIA309.71-1.14 -0.37%
IXIC11,322.24+194.39 1.75%

BRIEF-MEI Pharma, Kyowa Kirin Report Clinical Data On Zandelisib At European Hematology Association 2022 Hybrid Congress

reuters.com · 06/10/2022 03:09
BRIEF-MEI Pharma, Kyowa Kirin Report Clinical Data On Zandelisib At European Hematology Association 2022 Hybrid Congress

- Mei Pharma Inc MEIP:

  • MEI PHARMA AND KYOWA KIRIN REPORT CLINICAL DATA ON ZANDELISIB AT EUROPEAN HEMATOLOGY ASSOCIATION 2022 HYBRID CONGRESS

  • ZANDELISIB DEMONSTRATED 70.3% OBJECTIVE RESPONSE RATE AND 35.2% COMPLETE RESPONSE RATE

  • 9.9% OF PATIENTS DISCONTINUED THERAPY DUE TO A DRUG RELATED ADVERSE EVENT

Source text for Eikon: ID:nBw3gHhSba

Further company coverage: MEIP


((Reuters.Briefs@thomsonreuters.com;))